Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by themagicboxon Jan 16, 2020 11:54am

300 Views

Post# 30560658

Looks like the John Wallace is hoping for a buyout as well!

https://pharmaboardroom.com/articles/global-pharma-has-reinvented-rd-will-canadian-start-ups-lead-the-next-phase

TL;DR The founder of Antibe Theraputics says Big pharma is not focusing on R&D anymore and letting drug development pharmaceuticals do the work. They shop for the best pipelines thats in line with their company's objectives.

Good read fromt the founder! Did I mention it was John L. Wallace? lol

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features